<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01226290</url>
  </required_header>
  <id_info>
    <org_study_id>CL02413</org_study_id>
    <nct_id>NCT01226290</nct_id>
  </id_info>
  <brief_title>Fibroid Ablation Study</brief_title>
  <acronym>FAST-EU</acronym>
  <official_title>Symptom Effectiveness Study of VizAblate™ Intrauterine Ultrasound-Guided RF Ablation (IUUSgRFA) in the Ablation of Uterine Fibroids</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gynesonics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gynesonics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to establish the effectiveness and confirm the safety&#xD;
      of the VizAblate System in ablating symptomatic uterine fibroids.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Investigational device changes; adequate enrollment achieved&#xD;
  </why_stopped>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean percentage change in target fibroid perfused volume</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>procedure through 12 mo</time_frame>
    <description>Procedure safety will be assessed by recording all adverse events that occur on the day of the procedure. Longer-term safety will be assessed by recording at each follow-up visit any untoward medical occurrence since baseline. Each adverse event will be assessed for severity and relationship to study device.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage reduction in Menstrual Pictogram score</measure>
    <time_frame>baseline through 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage reduction in the Symptom Severity Subscale (SSS) of the Uterine Fibroid Symptom and Quality of Life (UFS-QOL) questionnaire</measure>
    <time_frame>baseline through 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of surgical reintervention for menorrhagia</measure>
    <time_frame>through 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Return to normal daily activity</measure>
    <time_frame>2 weeks or until returned to normal activity</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Subject satisfaction</measure>
    <time_frame>3 month, 6 month, 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Anesthesia regimen</measure>
    <time_frame>Day of procedure</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>System ease of use</measure>
    <time_frame>End of study</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Subject pain and tolerance of procedure</measure>
    <time_frame>Day of procedure</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>HRQL sub scale of Uterine Fibroid Symptom Quality of Life (UFS-QOL) questionnaire</measure>
    <time_frame>3 month, 6 month, 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>EuroQOL EQ-5D</measure>
    <time_frame>3 month, 6 month, 12 month</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Length of Stay</measure>
    <time_frame>Day of procedure</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Nonsurgical reintervention for menorrhagia</measure>
    <time_frame>30 day, 3 month, 6 month, 12 month</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Leiomyoma</condition>
  <condition>Uterine Fibroids</condition>
  <condition>Menorrhagia</condition>
  <arm_group>
    <arm_group_label>VizAblate treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VizAblate System: subject acts as her own control</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>VizAblate System</intervention_name>
    <description>VizAblate enables a minimally invasive procedure to visualize, target, and ablate uterine fibroids using intrauterine ultrasound and radiofrequency (RF) energy.</description>
    <arm_group_label>VizAblate treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  28 years of age or older&#xD;
&#xD;
          -  Regular, consistent menstrual cycles&#xD;
&#xD;
          -  History of excessive bleeding&#xD;
&#xD;
          -  One Menstrual Pictogram score ≥ 120 during a one-month screening period&#xD;
&#xD;
          -  Baseline Uterine Fibroid Symptom &amp; Quality of Life (UFS-QOL) Symptom Severity Subscale&#xD;
             (SSS) score ≥ 20&#xD;
&#xD;
          -  Between 1 and 5 Target Fibroids between 1 cm and 5 cm and/or maximum volume 82.4cc&#xD;
&#xD;
          -  At least one fibroid must indent the endometrium&#xD;
&#xD;
          -  Subject is not at material risk for pregnancy.&#xD;
&#xD;
          -  Subject is willing to maintain use or non-use of hormonal contraception&#xD;
&#xD;
          -  Subject is willing to have uniform maintenance (use or non-use) of any&#xD;
             antifibrinolytic or nonsteroidal anti-inflammatory agents&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subserosal fibroids with bulk symptoms&#xD;
&#xD;
          -  Presence of type 0 intracavitary fibroids&#xD;
&#xD;
          -  Any Target Fibroid &gt; 5 cm in maximum diameter with a volume &gt; 82.4cc&#xD;
&#xD;
          -  Any fibroid that obstructs access of the VizAblate probe&#xD;
&#xD;
          -  Postmenopausal by history&#xD;
&#xD;
          -  Desire for current or future fertility&#xD;
&#xD;
          -  Hemoglobin &lt; 6 g/dl&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Evidence of disorders of hemostasis&#xD;
&#xD;
          -  Use of Gonadotropin-releasing hormone (GnRH) agonist or implantable or injectable&#xD;
             progestin and/or estrogen, Selective Estrogen Receptor Modulators (SERM) or selective&#xD;
             progesterone receptor modulator (SPRM)&#xD;
&#xD;
          -  Short-term use of hormonal medication for management of bleeding&#xD;
&#xD;
          -  Evidence for current cervical dysplasia&#xD;
&#xD;
          -  Endometrial hyperplasia&#xD;
&#xD;
          -  Confirmed abdominal / pelvic malignancy within the previous five years&#xD;
&#xD;
          -  Active pelvic infection&#xD;
&#xD;
          -  Clinically significant adenomyosis&#xD;
&#xD;
          -  Previous uterine artery embolization. Previous surgical or ablative treatment for&#xD;
             fibroids or menorrhagia within previous 12 months&#xD;
&#xD;
          -  Current use of anticoagulant therapy&#xD;
&#xD;
          -  Need for emergency surgery to treat fibroid symptoms&#xD;
&#xD;
          -  Concomitant intrauterine polyps &gt; 1.0 cm&#xD;
&#xD;
          -  Contraindication to MRI&#xD;
&#xD;
          -  Renal insufficiency&#xD;
&#xD;
          -  Uncontrolled hypertension lasting 2 years or more&#xD;
&#xD;
          -  One or more treatable fibroids that are calcified&#xD;
&#xD;
          -  Chronic pelvic pain&#xD;
&#xD;
          -  Presence of an extrauterine pelvic mass&#xD;
&#xD;
          -  Presence of a tubal implant for sterilization&#xD;
&#xD;
          -  Previous pelvic irradiation&#xD;
&#xD;
          -  Endometrial cavity length &lt; 4.5 cm&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>28 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Toub, MD</last_name>
    <role>Study Director</role>
    <affiliation>Gynesonics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universidad Autonoma de Nuevo Leon (UANL)</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo Leon</state>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Máxima Medisch Centrum</name>
      <address>
        <city>Veldhoven</city>
        <state>Noord-Brabant</state>
        <zip>5500</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vrije Universiteit Medisch Centrum</name>
      <address>
        <city>Amsterdam</city>
        <state>North Holland</state>
        <zip>1007</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Antonius Ziekenhuis</name>
      <address>
        <city>Nieuwegein</city>
        <state>Utrecht</state>
        <zip>3430</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medisch Spectrum Twente</name>
      <address>
        <city>Enschede</city>
        <zip>7513 ER</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal London Hospital</name>
      <address>
        <city>Whitechapel</city>
        <state>London</state>
        <zip>E1 1BB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Birmingham Women's NHS Foundation Trust</name>
      <address>
        <city>Birmingham</city>
        <state>West Midlands</state>
        <zip>B15 2TG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Royal Hospital</name>
      <address>
        <city>Haywards Health</city>
        <state>West Sussex</state>
        <zip>RH16 3EJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bradford Teaching Hospitals NHS Trust</name>
      <address>
        <city>Bradford</city>
        <state>West Yorkshire</state>
        <zip>BD9 6RJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University College Hospital</name>
      <address>
        <city>London</city>
        <zip>NW1 2BU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <study_first_submitted>October 20, 2010</study_first_submitted>
  <study_first_submitted_qc>October 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 22, 2010</study_first_posted>
  <disposition_first_submitted>March 13, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>March 13, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 2, 2015</disposition_first_posted>
  <last_update_submitted>March 13, 2015</last_update_submitted>
  <last_update_submitted_qc>March 13, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>uterine fibroid RF ablation</keyword>
  <keyword>intrauterine ultrasound</keyword>
  <keyword>VizAblate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leiomyoma</mesh_term>
    <mesh_term>Myofibroma</mesh_term>
    <mesh_term>Menorrhagia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

